{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T14:04:39Z","timestamp":1778508279150,"version":"3.51.4"},"reference-count":165,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.clml.2011.10.003","type":"journal-article","created":{"date-parts":[[2011,12,16]],"date-time":"2011-12-16T19:06:09Z","timestamp":1324062369000},"page":"94-105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Novel Combination Treatments Targeting Chronic Myeloid Leukemia Stem Cells"],"prefix":"10.1016","volume":"12","author":[{"given":"Tareq","family":"Al Baghdadi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafat","family":"Abonour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Scott","family":"Boswell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2011.10.003_bib2","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.10.003_bib3","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.10.003_bib4","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1182\/blood.V110.11.1951.1951","article-title":"Imatinib resistance and\/or intolerance in clinical practice in Europe","volume":"110","author":"Michallet","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.003_bib5","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1038\/leu.2008.225","article-title":"A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials","volume":"22","author":"Lucas","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2011.10.003_bib6","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.6595","article-title":"Resistance to imatinib among patients in chronic phase (CP) of chronic myelogenous leukemia (CML) in clinical practice","volume":"26","author":"Davis","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.10.003_bib7","doi-asserted-by":"crossref","first-page":"6322","DOI":"10.1182\/blood-2008-11-186817","article-title":"Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up","volume":"113","author":"Kantarjian","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.003_bib8","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","article-title":"Nilotinib is effective in patients with chronic myeloid leukemia in CP after imatinib resistance or intolerance: 24-month follow-up results","volume":"117","author":"Kantarjian","year":"2011","journal-title":"Blood"},{"issue":"suppl","key":"10.1016\/j.clml.2011.10.003_bib9","article-title":"Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib (IM) resistance or intolerance: longer follow-up results of a phase II study","volume":"27","author":"Le Coutre","year":"2009","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.clml.2011.10.003_bib10","article-title":"Use of nilotinib to induce responses with 24-month (mo) minimum follow-up in patients (pts) with chronic myeloid leukemia in blast crisis (CML-BC) resistant to or intolerant of imatinib","volume":"28","author":"Giles","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.10.003_bib11","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1002\/cncr.25123","article-title":"Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study","volume":"116","author":"Saglio","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2011.10.003_bib12","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3324\/haematol.2009.011452","volume":"95","author":"Shah","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2011.10.003_bib13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.003_bib14","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1182\/blood.V99.10.3792","article-title":"Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation","volume":"99","author":"Holtz","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.003_bib15","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood-2004-03-1114","article-title":"Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment","volume":"105","author":"Chu","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.003_bib16","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction","volume":"107","author":"Copland","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.003_bib17","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1182\/blood-2006-11-057521","article-title":"Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells","volume":"109","author":"J\u00f8rgensen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.003_bib18","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.1182\/blood-2008-08-176016","article-title":"Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib","volume":"114","author":"Lemoli","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.003_bib19","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1172\/JCI41246","article-title":"Chronic myeloid leukemia: mechanisms of blastic transformation","volume":"120","author":"Perrotti","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clml.2011.10.003_bib20","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1007\/s12185-010-0615-8","article-title":"Molecular pathways to CML stem cells","volume":"91","author":"Rice","year":"2010","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2011.10.003_bib21","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.10.003_bib22","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/306277a0","article-title":"Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia","volume":"306","author":"Bartram","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.clml.2011.10.003_bib23","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0092-8674(84)90077-1","article-title":"Philadelphia chromosome breakpoints are clustered within a limited region, bcr, on chromosome 22","volume":"36","author":"Groffen","year":"1984","journal-title":"Cell"},{"key":"10.1016\/j.clml.2011.10.003_bib24","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.2408149","article-title":"Tyrosine kinase activity and transformation potency of bcr-abl oncogene products","volume":"247","author":"Lugo","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.clml.2011.10.003_bib25","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1158\/1078-0432.CCR-09-3314","article-title":"Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome\u2013positive leukemia","volume":"17","author":"O'Hare","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2011.10.003_bib26","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of bcr-abl1 positive chronic myeloid leukemia","volume":"113","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.003_bib27","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2011.10.003_bib28","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1182\/blood-2004-01-0246","article-title":"Imatinib targets other than bcr\/abl and their clinical relevance in myeloid disorders","volume":"104","author":"Pardanani","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.003_bib29","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed CP myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.10.003_bib30","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1200\/JCO.2009.26.5819","article-title":"Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib","volume":"28","author":"White","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.10.003_bib31","doi-asserted-by":"crossref","first-page":"250","DOI":"10.4161\/cc.10.2.14537","article-title":"Impact of BCR-ABL mutations on patients with chronic myeloid leukemia","volume":"10","author":"Hochhaus","year":"2011","journal-title":"Cell Cycle"},{"key":"10.1016\/j.clml.2011.10.003_bib32","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.10.003_bib33","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.003_bib34","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.669.669","article-title":"Molecular response <1% BCR-ABL IS at 12 months is associated with improved overall and progression-free survival","volume":"116","author":"M\u00fcller","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.003_bib35","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays","volume":"47","author":"Lombardo","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/j.clml.2011.10.003_bib36","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1124\/mol.105.020172","article-title":"Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib)","volume":"69","author":"Chen","year":"2006","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.clml.2011.10.003_bib37","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/0008-5472.CAN-05-2050","article-title":"Dasatinib (BMS-354825), a dual SRC\/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies","volume":"66","author":"Schittenhelm","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2011.10.003_bib38","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","article-title":"The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants","volume":"66","author":"Tokarski","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2011.10.003_bib39","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1182\/blood-2007-10-116236","article-title":"Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia","volume":"112","author":"Giannoudis","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.003_bib40","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1158\/1078-0432.CCR-07-5095","article-title":"Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications","volume":"14","author":"Hiwase","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2011.10.003_bib41","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant abl kinase domain mutants","volume":"65","author":"O'Hare","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2011.10.003_bib42","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1182\/blood-2006-09-046888","article-title":"Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis","volume":"109","author":"Cortes","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.003_bib43","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2008.84","article-title":"Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in CP with resistance or intolerance to imatinib","volume":"22","author":"Hochhaus","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2011.10.003_bib44","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1200\/JCO.2007.14.3339","article-title":"Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START A trial","volume":"27","author":"Apperley","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.10.003_bib45","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed CP chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.10.003_bib46","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.6510","article-title":"Dasatinib or imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Two-year follow-up from DASISION","volume":"29","author":"Kantarjian","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.10.003_bib47","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2011.10.003_bib48","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.10.003_bib49","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","article-title":"Nilotinib versus imatinib for the treatment of patients with newly diagnosed CP, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial","volume":"12","author":"Kantarjian","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2011.10.003_bib50","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","article-title":"Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome\u2013positive chronic myeloid leukemia patients with resistance or intolerance to imatinib","volume":"118","author":"Cortes","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.003_bib51","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1365-2362.2006.01645.x","article-title":"In vivo effects of imatinib mesylate on human haematopoietic progenitor cells","volume":"36","author":"Agis","year":"2006","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.clml.2011.10.003_bib52","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.1428.1428","article-title":"Combination of the hedgehog pathway inhibitor LDE225 and nilotinib eliminates chronic myeloid leukemia stem and progenitor cells","volume":"114","author":"Irvine","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.003_bib53","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/leu.2008.262","article-title":"beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia","volume":"23","author":"Hu","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2011.10.003_bib54","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Corbin","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clml.2011.10.003_bib55","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/leu.2010.185","article-title":"Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR","volume":"24","author":"Ross","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2011.10.003_bib56","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1182\/blood-2011-02-335497","article-title":"Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease","volume":"118","author":"Chomel","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.003_bib57","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2011.10.003_bib58","doi-asserted-by":"crossref","first-page":"6812","DOI":"10.1158\/1078-0432.CCR-11-0396","article-title":"BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatment","volume":"17","author":"Stein","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2011.10.003_bib59","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1182\/blood-2011-02-339267","article-title":"Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells","volume":"118","author":"Tang","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.003_bib60","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1182\/blood.V87.4.1539.bloodjournal8741539","article-title":"Normal and leukemic SCID-repopulating cells (SRC) coexist in the bone marrow and peripheral blood from CML patients in CP, whereas leukemic SRC are detected in blast crisis","volume":"87","author":"Sirard","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.003_bib61","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1182\/blood.V93.1.284","article-title":"BCR\/ABL\u2013CD34+ HLA-DR\u2013 progenitor cells in early CP, but not in more advanced phases, of chronic myelogenous leukemia are polyclonal","volume":"93","author":"Delforge","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.003_bib62","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1182\/blood.V86.2.737.bloodjournal862737","article-title":"Benign marrow progenitors are enriched in the CD34+\/HLA-DRlopopulation but not in the CD34+\/CD38lo population in chronic myeloid leukemia: an analysis using interphase fluorescence in situ hybridization","volume":"86","author":"Kirk","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.003_bib63","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/sj.leu.2404609","article-title":"Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies","volume":"21","author":"Jiang","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2011.10.003_bib64","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/sj.leu.2402444","article-title":"Elucidating critical mechanisms of deregulated stem cell turnover in the CP of chronic myeloid leukemia","volume":"16","author":"Holyoake","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2011.10.003_bib65","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1182\/blood.V94.6.2056","article-title":"Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia","volume":"94","author":"Holyoake","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.003_bib66","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/MOH.0b013e328303e14c","article-title":"Evolving concepts on the microenvironmental niche for hematopoietic stem cells","volume":"15","author":"Raaijmakers","year":"2008","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.clml.2011.10.003_bib67","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1053\/j.seminhematol.2010.06.006","article-title":"The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it?","volume":"47","author":"Carter","year":"2010","journal-title":"Semin Hematol"},{"key":"10.1016\/j.clml.2011.10.003_bib68","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/nm1489","article-title":"Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells","volume":"12","author":"Krause","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2011.10.003_bib69","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1038\/leu.2010.159","article-title":"Insights into the stem cells of chronic myeloid leukemia","volume":"24","author":"Sloma","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2011.10.003_bib70","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1182\/blood.V90.1.64.64_64_69","article-title":"Selective expansion of primitive normal hematopoietic cells in cytokine-supplemented cultures of purified cells from patients with chronic myeloid leukemia","volume":"90","author":"Petzer","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.003_bib71","doi-asserted-by":"crossref","first-page":"6192","DOI":"10.1073\/pnas.89.13.6192","article-title":"Rapid decline of chronic myeloid leukemic cells in long-term culture due to a defect at the leukemic stem cell level","volume":"89","author":"Udomsakdi","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2011.10.003_bib72","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/10428190500272507","article-title":"Detection of molecular targets on the surface of CD34+\/CD38\u2013 stem cells in various myeloid malignancies","volume":"47","author":"Florian","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2011.10.003_bib73","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/nm.2415","article-title":"Stem cell gene expression programs influence clinical outcome in human leukemia","volume":"17","author":"Eppert","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2011.10.003_bib74","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.bbamcr.2006.11.017","article-title":"TGFbeta1 regulation of vimentin gene expression during differentiation of the C2C12 skeletal myogenic cell line requires Smads, AP-1 and Sp1 family members","volume":"1773","author":"Wu","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.clml.2011.10.003_bib75","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/sj.leu.2404549","article-title":"Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in CP","volume":"21","author":"Diaz-Blanco","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2011.10.003_bib76","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1182\/blood-2010-02-270660","article-title":"BMI1 collaborates with BCR-ABL in leukemic transformation of human CD34+ cells","volume":"116","author":"Rizo","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.003_bib77","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1182\/blood-2006-12-065599","article-title":"The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia","volume":"110","author":"Mohty","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.003_bib78","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2217\/nnm.10.8","article-title":"Imatinib-loaded polyelectrolyte microcapsules for sustained targeting of BCR-ABL+ leukemia stem cells","volume":"5","author":"Palam\u00e0","year":"2010","journal-title":"Nanomedicine (Lond)"},{"key":"10.1016\/j.clml.2011.10.003_bib79","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nature08734","article-title":"TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia","volume":"463","author":"Naka","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.clml.2011.10.003_bib80","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJMoa040258","article-title":"Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML","volume":"351","author":"Jamieson","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.10.003_bib81","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ccr.2007.11.003","article-title":"Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo","volume":"12","author":"Zhao","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2011.10.003_bib82","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.2168.2168","article-title":"Wnt pathway-directed compound targets blast crisis and CP CML leukemia stem progenitors","volume":"114","author":"Peterson","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.003_bib83","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.1081.1081","article-title":"A novel b-catenin inhibitor, AV65 suppresses the growth of CML cell lines which acquire imatinib-resistance because of Abl kinase domain mutations including T315I and hypoxia-adaptation","volume":"112","author":"Nagao","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.003_bib84","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.2184.2184","article-title":"Inhibition of Wnt\/\u03b2-catenin signaling by AV65 treatment caused cell cycle arrest and induced caspase-independent or -dependent apoptosis in CML cells","volume":"114","author":"Nagao","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.003_bib85","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ccr.2010.04.025","article-title":"Wnt\/Ca2+\/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl","volume":"18","author":"Gregory","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2011.10.003_bib86","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/nri2818","article-title":"NFAT, immunity and cancer: a transcription factor comes of age","volume":"10","author":"Muller","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.clml.2011.10.003_bib87","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1182\/blood.V92.7.2450","article-title":"Regulation of the c-jun gene in p210 BCR-ABL transformed cells corresponds with activity of JNK, the c-jun N-terminal kinase","volume":"92","author":"Burgess","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.003_bib88","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/1758834010366430","article-title":"Targeting the hedgehog pathway in cancer","volume":"2","author":"Gupta","year":"2010","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.clml.2011.10.003_bib89","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ccr.2008.08.003","article-title":"Expansion of Bcr-Abl\u2013positive leukemic stem cells is dependent on hedgehog pathway activation","volume":"14","author":"Dierks","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2011.10.003_bib90","doi-asserted-by":"crossref","first-page":"e15262","DOI":"10.1371\/journal.pone.0015262","article-title":"Self-renewal of acute lymphocytic leukemia cells is limited by the hedgehog pathway inhibitors cyclopamine and IPI-926","volume":"5","author":"Lin","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.clml.2011.10.003_bib91","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1756-9966-30-8","article-title":"Activation of the hedgehog pathway in chronic myelogeneous leukemia patients","volume":"30","author":"Long","year":"2011","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.clml.2011.10.003_bib92","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nature07737","article-title":"Hedgehog signaling is essential for maintenance of cancer stem cells in myeloid leukemia","volume":"458","author":"Zhao","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.clml.2011.10.003_bib93","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1200\/jco.2010.28.15_suppl.2501","article-title":"A first-in-human, phase I study of an oral hedgehog (HH) pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors","volume":"28","author":"Siu","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.10.003_bib94","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1158\/1078-0432.CCR-10-2745","article-title":"Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors","volume":"17","author":"LoRusso","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2011.10.003_bib95","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1056\/NEJMoa0902903","article-title":"Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449","volume":"361","author":"Rudin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.10.003_bib96","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1097\/01.cmr.0000382826.44113.f0","article-title":"FC24 LDE225, a specific smoothened inhibitor, for the topical treatment of nevoid basal cell carcinoma syndrome (Gorlin's syndrome)","volume":"20","author":"Stuetz","year":"2010","journal-title":"Melanoma Res"},{"issue":"suppl","key":"10.1016\/j.clml.2011.10.003_bib97","article-title":"A phase I dose-escalation study of LDE225, a smoothened (SMO) antagonist, in patients with advanced solid tumors","volume":"28","author":"Ahnert","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.10.003_bib98","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/00062752-200207000-00010","article-title":"Histone deacetylases as therapeutic targets in hematologic malignancies","volume":"9","author":"Melnick","year":"2002","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.clml.2011.10.003_bib99","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ccr.2010.03.011","article-title":"Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate","volume":"17","author":"Zhang","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2011.10.003_bib100","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-06-0980","article-title":"Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells","volume":"12","author":"Fiskus","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2011.10.003_bib101","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood-2005-11-4639","article-title":"Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl\u2013expressing human leukemia cells","volume":"108","author":"Fiskus","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.003_bib102","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1182\/blood-2002-08-2675","article-title":"Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells","volume":"101","author":"Nimmanapalli","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.003_bib103","first-page":"5126","article-title":"Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells","volume":"63","author":"Nimmanapalli","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2011.10.003_bib104","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1182\/blood-2007-10-116376","article-title":"Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia (CML) cells sensitive and resistant to imatinib mesylate","volume":"112","author":"Dai","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.003_bib105","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1038\/sj.leu.2403519","article-title":"Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo","volume":"18","author":"Weisberg","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2011.10.003_bib106","doi-asserted-by":"crossref","first-page":"26729","DOI":"10.1074\/jbc.C500186200","article-title":"Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors","volume":"280","author":"Bali","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clml.2011.10.003_bib107","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1182\/blood.V110.11.1031.1031","article-title":"Effective induction of apoptosis in chronic myeloid leukemia CD34+ cells by the histone deacetylase inhibitor LAQ824 in combination with imatinib","volume":"110","author":"Strauss","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.003_bib108","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.1182\/blood-2009-05-222133","article-title":"Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells","volume":"114","author":"Wang","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.003_bib109","doi-asserted-by":"crossref","first-page":"939","DOI":"10.4161\/cbt.8.10.8213","article-title":"Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells","volume":"8","author":"Fiskus","year":"2009","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.clml.2011.10.003_bib110","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1101\/gad.7.3.479","article-title":"JunB differs from c-Jun in its DNA-binding and dimerization domains, and represses c-Jun by formation of inactive heterodimers","volume":"7","author":"Deng","year":"1993","journal-title":"Genes Dev"},{"key":"10.1016\/j.clml.2011.10.003_bib111","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.cell.2004.10.010","article-title":"JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells","volume":"119","author":"Passegu\u00e9","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.clml.2011.10.003_bib112","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1200\/JCO.2005.11.981","article-title":"Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate","volume":"23","author":"Issa","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.10.003_bib113","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.leukres.2010.01.030","article-title":"Bcr-Abl-independent mechanism of resistance to imatinib in K562 cells: induction of cyclooxygenase-2 (COX-2) by histone deacetylases (HDACs)","volume":"34","author":"Kalle","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2011.10.003_bib114","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.958.958","article-title":"Phase IA\/II study of oral panobinostat (LBH589), a novel pan-deacetylase inhibitor (DACi) demonstrating efficacy in patients with advanced hematologic malignancies","volume":"112","author":"Ottmann","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.003_bib115","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.2194.2194","article-title":"A phase I study of the HDAC inhibitor LBH589 in combination with imatinib for patients with CML in cytogenetic remission with residual disease detectable by Q-PCR","volume":"114","author":"Bhatia","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.003_bib117","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/leu.2009.52","article-title":"Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice","volume":"23","author":"Chen","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2011.10.003_bib118","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood.V86.9.3322.bloodjournal8693322","article-title":"Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late CP","volume":"86","author":"O'Brien","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.003_bib119","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1002\/cncr.10436","article-title":"Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia","volume":"94","author":"O'Brien","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2011.10.003_bib120","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.1200\/JCO.2000.18.20.3513","article-title":"Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia","volume":"18","author":"Kantarjian","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.10.003_bib121","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/cncr.11620","article-title":"Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome\u2013positive chronic myelogenous leukemia in early CP","volume":"98","author":"O'Brien","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2011.10.003_bib122","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1002\/cncr.20975","article-title":"Phase I\/II study of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib","volume":"103","author":"Marin","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2011.10.003_bib123","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/cncr.22398","article-title":"Phase I\/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy","volume":"109","author":"Quint\u00e1s-Cardama","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2011.10.003_bib124","article-title":"Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients who harbor the Bcr- Abl T315I mutation\u2013results of an ongoing multicenter phase 2\/3 study","volume":"114","author":"Cortes-Franco","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.003_bib125","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1182\/blood-2004-02-0749","article-title":"Identification of mcl-1 as a BCR\/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides","volume":"105","author":"Aichberger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.003_bib126","doi-asserted-by":"crossref","first-page":"14907","DOI":"10.1073\/pnas.0606176103","article-title":"Bim and Bad mediate imatinib-induced killing of Bcr\/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic","volume":"103","author":"Kuroda","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2011.10.003_bib127","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/1042819031000139710","article-title":"Triptolide down-regulates bcr-abl expression and induces apoptosis in chronic myelogenous leukemia cells","volume":"45","author":"Lou","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2011.10.003_bib128","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1158\/1535-7163.MCT-09-0386","article-title":"Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells","volume":"8","author":"Mak","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clml.2011.10.003_bib129","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1158\/1078-0432.CCR-08-2141","article-title":"Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation","volume":"15","author":"Shi","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2011.10.003_bib130","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2141.2007.06899.x","article-title":"ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms","volume":"140","author":"Kuroda","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2011.10.003_bib131","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.646.646","article-title":"Inhibition of Bcl-2\/Bcl-XL Promotes apoptosis in blast crisis CML including quiescent primitive progenitor cells regardless of cellular responses to tyrosine kinase inhibitors","volume":"114","author":"Mak","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.003_bib132","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/nature07016","article-title":"PML targeting eradicates quiescent leukemia-initiating cells","volume":"453","author":"Ito","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.clml.2011.10.003_bib133","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/ng.389","article-title":"Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia","volume":"41","author":"Chen","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.clml.2011.10.003_bib135","doi-asserted-by":"crossref","first-page":"28570","DOI":"10.1074\/jbc.M011685200","article-title":"The p38 MAPK pathway mediates the growth inhibitory effects of interferon-alpha in BCR-ABL-expressing cells","volume":"276","author":"Mayer","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clml.2011.10.003_bib136","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0145-2126(02)00347-8","article-title":"Involvement of protein phosphatase 2A in interferon-alpha-2b\u2013induced apoptosis in K562 human chronic myelogenous leukaemia cells","volume":"27","author":"Saydam","year":"2003","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2011.10.003_bib137","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1182\/blood-2004-10-4003","article-title":"Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells","volume":"106","author":"Parmar","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.003_bib138","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1365-2141.2005.05606.x","article-title":"Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors","volume":"130","author":"Angstreich","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2011.10.003_bib139","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.003_bib140","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1182\/blood.V95.1.62","article-title":"Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission","volume":"95","author":"Hochhaus","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.003_bib141","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nature07815","article-title":"IFNalpha activates dormant haematopoietic stem cells in vivo","volume":"458","author":"Essers","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.clml.2011.10.003_bib142","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/nm.1973","article-title":"Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon-dependent exhaustion","volume":"15","author":"Sato","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2011.10.003_bib143","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.3324\/haematol.2009.021246","article-title":"The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early CP","volume":"95","author":"Palandri","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2011.10.003_bib144","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia","volume":"363","author":"Preudhomme","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.10.003_bib145","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1200\/JCO.2009.25.5075","article-title":"Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia","volume":"28","author":"Burchert","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.10.003_bib146","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1016\/S0092-8674(02)00701-8","article-title":"Cytokine signaling in 2002: new surprises in the Jak\/Stat pathway","volume":"109","author":"O'Shea","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.clml.2011.10.003_bib147","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1038\/sj.onc.1205398","article-title":"JAKs, STATs and Src kinases in hematopoiesis","volume":"21","author":"Rane","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.clml.2011.10.003_bib148","doi-asserted-by":"crossref","first-page":"6188","DOI":"10.1038\/sj.onc.1204834","article-title":"Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation","volume":"20","author":"Xie","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.clml.2011.10.003_bib149","doi-asserted-by":"crossref","first-page":"7137","DOI":"10.1038\/sj.onc.1205942","article-title":"Jak2 is involved in c-Myc induction by Bcr-Abl","volume":"21","author":"Xie","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.clml.2011.10.003_bib150","doi-asserted-by":"crossref","first-page":"6468","DOI":"10.1158\/0008-5472.CAN-06-0025","article-title":"Janus kinase 2: a critical target in chronic myelogenous leukemia","volume":"66","author":"Samanta","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2011.10.003_bib151","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1084\/jem.20072316","article-title":"AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem\/progenitor cells","volume":"205","author":"Zhou","year":"2008","journal-title":"J Exp Med"},{"key":"10.1016\/j.clml.2011.10.003_bib152","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1177\/1947601910371337","article-title":"A non-ATP\u2013competitive dual inhibitor of JAK2 and BCR-ABL kinases: elucidation of a novel therapeutic spectrum based on substrate competitive inhibition","volume":"1","author":"Jatiani","year":"2010","journal-title":"Genes Cancer"},{"key":"10.1016\/j.clml.2011.10.003_bib153","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1177\/1947601910372232","article-title":"Destabilization of Bcr-Abl\/Jak2 network by a Jak2\/Abl kinase inhibitor ON044580 overcomes drug resistance in blast crisis chronic myelogenous leukemia (CML)","volume":"1","author":"Samanta","year":"2010","journal-title":"Genes Cancer"},{"key":"10.1016\/j.clml.2011.10.003_bib154","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.38.38","article-title":"A Novel AHI-1-BCR-ABL-JAK2 interaction complex mediates cellular resistance to tyrosine kinase inhibitors in CML","volume":"114","author":"DeGeer","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.003_bib155","first-page":"355","article-title":"The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome","volume":"11","author":"An","year":"2000","journal-title":"Cell Growth Differ"},{"key":"10.1016\/j.clml.2011.10.003_bib156","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.1182\/blood-2009-10-247239","article-title":"Heat shock protein 90 regulates the expression of Wilms' tumor 1 protein in myeloid leukemias","volume":"116","author":"Bansal","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.003_bib157","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/ajh.21915","article-title":"Characterization of chronic myeloid leukemia stem cells","volume":"86","author":"Gerber","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2011.10.003_bib158","doi-asserted-by":"crossref","first-page":"393","DOI":"10.4149\/neo_2009_05_393","article-title":"WT1 expression in peripheral leukocytes of patients with chronic myeloid leukemia serves for the prediction of imatinib resistance","volume":"56","author":"Otahalova","year":"2009","journal-title":"Neoplasma"},{"key":"10.1016\/j.clml.2011.10.003_bib159","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3109\/10428194.2010.550978","article-title":"Role of hTERT and WT1 gene expression in disease progression and imatinib responsiveness of patients with BCR-ABL positive chronic myeloid leukemia","volume":"52","author":"Varma","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2011.10.003_bib160","first-page":"1799","article-title":"Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts","volume":"61","author":"Nimmanapalli","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2011.10.003_bib161","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.1021\/jm0603116","article-title":"Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90","volume":"49","author":"Ge","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.clml.2011.10.003_bib162","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/blood-2006-10-054098","article-title":"Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemia stem cells","volume":"110","author":"Peng","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.003_bib164","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1038\/onc.2011.3","article-title":"Combined effects of novel heat shock protein 90 inhibitor NVP-AUY922 and nilotinib in a random mutagenesis screen","volume":"30","author":"Tauchi","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.clml.2011.10.003_bib165","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.2174\/092986711796011256","article-title":"Molecular chaperone hsp90 as a target for oxidant-based anticancer therapies","volume":"18","author":"Beck","year":"2011","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.clml.2011.10.003_bib169","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1182\/blood.V100.3.1068","article-title":"Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336","volume":"100","author":"Hoover","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.003_bib170","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/sj.leu.2403785","article-title":"Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro","volume":"19","author":"Jorgensen","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2011.10.003_bib171","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/cncr.22901","article-title":"Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib","volume":"110","author":"Cortes","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2011.10.003_bib172","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1002\/cncr.23006","article-title":"Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in CP after imatinib failure","volume":"110","author":"Cortes","year":"2007","journal-title":"Cancer"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011005763?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011005763?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:22:30Z","timestamp":1761870150000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265011005763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":165,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S2152265011005763"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2011.10.003","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel Combination Treatments Targeting Chronic Myeloid Leukemia Stem Cells","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2011.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}